Volume 17 - Issue 4 - April 2009

Earlier this month, Genentech issued a voluntary U.S. market withdrawal of efalizumab (Raptiva). On April 8, the company sent a letter to physicians to inform them about the decision to implement a phased voluntary withdrawal of the psoriasis medication due to an increased risk of progressive multifocal leukoencephalopathy (PML) in patients on Raptiva therapy. The letter informs physicians not to prescribe Raptiva to any new patients and that Raptiva will only be available to current patients until June 8. The letter instructs physicians to “review the treatment of all patients who are curr